Targeting the yin and the yang: Combined inhibition of the tyrosine kinase c-Src and the tyrosine phosphatase SHP-2 disrupts pancreatic cancer signaling and biology in vitro and tumor formation in vivo

Pancreas

Volumn 42, Issue 5, 2013, Pages 795-806

  Gomes, Evan G ^a   Connelly, Sarah F ^a   Summy, Justin M ^a  

^a M D ANDERSON CANCER CENTER ORLANDO   (United States)

Author keywords

Akt; Apoptosis; Carcinoma; ERK 1 2; Invasion; Migration

Indexed keywords

CASPASE 3; CASPASE 7; DASATINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHENYLHYDRAZONOPYRAZOLONE SULFONATE 1; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; PROTEIN KINASE P60; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE SHP 2; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DRUG SYNERGISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; THIAZOLES; TUMOR BURDEN; VANADATES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84880064657     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3182793fd7     Document Type: Article

References (55)

1. MacKenzie MJ. Molecular therapy in pancreatic adenocarcinoma. Lancet Oncol. 2004;5:541-549.
2. Wolff RA. Chemotherapy for pancreatic cancer: from metastatic disease to adjuvant therapy. Cancer J. 2007;13:175-184.
3. Mimeault M, Brand RE, Sasson A.A., et al Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies. Pancreas. 2005;31:301-316.
4. Summy JM, Gallick GE Treatment for advanced tumors: SRC reclaims center stage. Clin Cancer Res. 2006;12:1398-1401.
5. Trevino JG, Summy JM, Gallick GE SRC inhibitors as potential therapeutic agents for human cancers. Mini Rev Med Chem. 2006;6:681-687.
6. Frame MC. Newest findings on the oldest oncogene; how activated src does it. J Cell Sci. 2004;117:989-998.
7. Brown MT, Cooper JA Regulation, substrates and functions of src. Biochim Biophys Acta. 1996;1287:121-149.
8. Wheeler DL, Iida M, Dunn EF The role of Src in solid tumors. Oncologist. 2009;14:667-678.
9. Lutz MP, Esser IB, Flossmann-Kast BB, et al Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Commun. 1998;243:503-508.
10. Chatzizacharias NA, Giaginis C, Zizi-Serbetzoglou D, et al Evaluation of the clinical significance of focal adhesion kinase and SRC expression in human pancreatic ductal adenocarcinoma. Pancreas. 2010;39:930-936.
11. Nagaraj NS, Smith JJ, Revetta F, et al Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis. Mol Cancer Ther. 2010;9:2322-2332.
12. Summy JM, Trevino JG, Baker C.H., et al c-Src regulates constitutive and EGF-mediated VEGF expression in pancreatic tumor cells through activation of phosphatidyl inositol-3 kinase and p38 MAPK. Pancreas. 2005;31:263-274.
13. Zeng H, Datta K, Neid M., et al Requirement of different signaling pathways mediated by insulin-like growth factor-I receptor for proliferation, invasion, and VPF/VEGF expression in a pancreatic carcinoma cell line. Biochem Biophys Res Commun. 2003;302:46-55.
14. Olszewska-Pazdrak B., Townsend CM Jr, Hellmich MR Agonist-independent activation of Src tyrosine kinase by a cholecystokinin-2 (CCK2) receptor splice variant. J Biol Chem. 2004;279(39):40400-40404.
15. Ferrand A, Vatinel S, Kowalski-Chauvel A, et al Mechanism for Src activation by the CCK2 receptor: patho-physiological functions of this receptor in pancreas. World J Gastroenterol. 2006;12:4498-4503.
16. Duxbury MS, Ito H, Benoit E., et al A novel role for carcinoembryonic antigen-related cell adhesion molecule 6 as a determinant of gemcitabine chemoresistance in pancreatic adenocarcinoma cells. Cancer Res. 2004;64:3987-3993.
17. Tsuda M, Matozaki T, Fukunaga K., et al Integrin-mediated tyrosine phosphorylation of SHPS-1 and its association with SHP-2. Roles of Fak and Src family kinases. J Biol Chem. 1998;273:13223-13229.
18. Desgrosellier JS, Barnes LA, Shields D.J., et al An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat Med. 2009;15:1163-1169.
19. Trevino JG, Summy JM, Lesslie D.P., et al Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol. 2006;168:962-972.
20. Yezhelyev MV, Koehl G, Guba M., et al Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin Cancer Res. 2004;10:8028-8036.
21. Morton JP, Karim SA, Graham K, et al Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology. 2010;139:292-303.
22. Zhang ZY. Functional studies of protein tyrosine phosphatases with chemical approaches. Biochim Biophys Acta. 2005;1754:100-107.
23. Poole AW, Jones ML A SHPing tale: perspectives on the regulation of SHP-1 and SHP-2 tyrosine phosphatases by the C-terminal tail. Cell Signal. 2005;17:1323-1332.
24. Inagaki K, Noguchi T, Matozaki T., et al Roles for the protein tyrosine phosphatase SHP-2 in cytoskeletal organization, cell adhesion and cell migration revealed by overexpression of a dominant negative mutant. Oncogene. 2000;19:75-84.
25. Cunnick JM, Meng S, Ren Y., et al Regulation of the mitogen-activated protein kinase signaling pathway by SHP2. J Biol Chem. 2002;277:9498-9504.
26. Maroun CR, Naujokas MA, Holgado-Madruga M, et al The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol Cell Biol. 2000;20:8513-8525.
27. Yart A, Mayeux P, Raynal P. Gab1, SHP-2 and other novel regulators of Ras: targets for anticancer drug discovery? Curr Cancer Drug Targets. 2003;3:177-192.
28. Mannell H, Hellwig N, Gloe T., et al Inhibition of the tyrosine phosphatase SHP-2 suppresses angiogenesis in vitro and in vivo. J Vasc Res. 2007;45:153-163.
29. Matozaki T, Murata Y, Saito Y., et al Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation. Cancer Sci. 2009;100:1786-1793.
30. Tsutsumi R, Takahashi A, Azuma T., et al Focal adhesion kinase is a substrate and downstream effector of SHP-2 complexed with Helicobacter pylori CagA. Mol Cell Biol. 2006;26:261-276.
31. Ren Y, Chen Z, Chen L., et al Critical role of Shp2 in tumor growth involving regulation of c-Myc. Genes Cancer. 2010;1:994-1007.
32. Bruns CJ, Harbison MT, Kuniyas H, et al In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia. 1999;1:50-62.
33. Lee KM, Yasuda H, Hollingsworth M.A., et al Notch 2-positive progenitors with the intrinsic ability to give rise to pancreatic ductal cells. Lab Invest. 2005;85:1003-1012.
34. Windham TC, Parikh NU, Siwak D.R., et al Src activation regulates anoikis in human colon tumor cell lines. Oncogene. 2002;21: 7797-7807.
35. Lu W, Gong D, Bar-Sagi D, et al Site-specific incorporation of a phosphotyrosine mimetic reveals a role for tyrosine phosphorylation of SHP-2 in cell signaling. Mol Cell. 2001;8:759-769.
36. Connelly SF, Isley BA, Baker C.H., et al Loss of tyrosine phosphatase-dependent inhibition promotes activation of tyrosine kinase c-Src in detached pancreatic cells. Mol Carcinog. 2010;49: 1007-1021.
37. Shah NP, Tran C, Lee F.Y., et al Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305:399-401.
38. Nicholson DW, Ali A, Thornberry N.A., et al Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 1995;376:37-43.
39. Tewari M, Quan LT, O'Rourke K, et al Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell. 1995;81:801-809.
40. Karnak D, Xu L. Chemosensitization of prostate cancer by modulating Bcl-2 family proteins. Curr Drug Targets. 2010;11:699-707.
41. Renault TT, Manon S. Bax: addressed to kill. Biochimie. 2011;93:1379-1391.
42. Hellmuth K, Grosskopf S, Lum C.T., et al Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking. Proc Natl Acad Sci U S A. 2008;105:7275-7280.
43. Ischenko I, Guba M, Yezhelyev M., et al Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer. Angiogenesis. 2007;10:167-182.
44. Duxbury MS, Ito H, Zinner M.J., et al siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity. J Am Coll Surg. 2004;198:953-959.
45. Duxbury MS, Ito H, Zinner M.J., et al Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res. 2004;10: 2307-2318.
46. Renouf DJ, Moore MJ, Hedley D, et al A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer. Invest New Drugs. 2012;30:779-786.
47. Doebele RC, Oton AB, Peled N, et al New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. Lung Cancer. 2010;69:1-12.
48. Awasthi N, Yen PL, Schwarz M.A., et al The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer. J Cell Biochem. 2012;113:784-791.
49. Vinall RL, Mahaffey CM, Davis R.R., et al Dual blockade of PKA and NF-kappaB inhibits H2 relaxin-mediated castrate-resistant growth of prostate cancer sublines and induces apoptosis. Horm Cancer. 2011;2:224-238.
50. Yuan L, Yu WM, Xu M, et al SHP-2 phosphatase regulates DNA damage-induced apoptosis and G2/M arrest in catalytically dependent and independent manners, respectively. J Biol Chem. 2005;280: 42701-42706.
51. Walter AO, Peng ZY, Cartwright CA The Shp-2 tyrosine phosphatase activates the Src tyrosine kinase by a non-enzymatic mechanism. Oncogene. 1999;18:1911-1920.
52. Zhang SQ, Yang W, Kontaridis M.I., et al Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol Cell. 2004;13:341-355.
53. Calvo E, Bolos V, Grande E. Multiple roles and therapeutic implications of Akt signaling in cancer. Onco Targets Ther. 2009;2:135-150.
54. Saif MW, Karapanagiotou L, Syrigos K. Genetic alterations in pancreatic cancer. World J Gastroenterol. 2007;13:4423-4430.
55. Roskoski R Jr. RAF protein-serine/threonine kinases: structure and regulation. Biochem Biophys Res Commun. 2010;399:313-317.